ZLAB - Zai Lab Ltd

Insider Sale by Amado Rafael (See Remarks)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

5 days ago, Amado Rafael, serving as See Remarks at Zai Lab Ltd (ZLAB), sold 2,957 shares at $18.63 per share, for a total transaction value of $55,083.00. Following this transaction, Amado Rafael now holds 44,757 shares of ZLAB.

This sale represents a 6.00% decrease in Amado Rafael's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, March 13, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 16, 2026, 3 days after the trade was made.

Zai Lab Ltd operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Amado Rafael

See Remarks

Rafael G. Amado, M.D. (referred to as Amado Rafael in some contexts) is President and Head of Global R&D at Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative biopharmaceutical company focused on oncology, autoimmune disorders, infectious diseases, and neuroscience.[[1]](https://www.citybiz.co/article/566031/zai-lab-appoints-rafael-amado-as-president-head-of-global-rd/)[[2]](https://www.nasdaq.com/press-release/zai-lab-announces-the-appointment-of-dr.-rafael-g.-amado-as-president-head-of-global) He assumed the role of Head of Global Oncology R&D in December 2022 and expanded to oversee all Global R&D following Harald Reinhart's retirement in June 2024.[[1]](https://www.citybiz.co/article/566031/zai-lab-appoints-rafael-amado-as-president-head-of-global-rd/)[[2]](https://www.nasdaq.com/press-release/zai-lab-announces-the-appointment-of-dr.-rafael-g.-amado-as-president-head-of-global)[[5]](https://firstwordpharma.com/story/5866019) As a key executive reporting to CEO Dr. Samantha Du, Dr. Amado leads global research, development, and pipeline advancement across therapy areas.[[1]](https://www.citybiz.co/article/566031/zai-lab-appoints-rafael-amado-as-president-head-of-global-rd/)[[2]](https://www.nasdaq.com/press-release/zai-lab-announces-the-appointment-of-dr.-rafael-g.-amado-as-president-head-of-global) Dr. Amado brings extensive expertise in oncology drug development, previously serving as Executive Vice President, Head of R&D and Chief Medical Officer at Allogene Therapeutics (2019–2022), President of R&D and CMO at Adaptimmune (2018–2019), and Senior Vice President and Global Head of Oncology R&D at GlaxoSmithKline (2008–2015), among other roles at Amgen and academic positions at UCLA.[[2]](https://www.nasdaq.com/press-release/zai-lab-announces-the-appointment-of-dr.-rafael-g.-amado-as-president-head-of-global) He earned his M.D. from the University of Seville School of Medicine, completed residency in Internal Medicine, and fellowship in Hematology/Oncology at UCLA.[[2]](https://www.nasdaq.com/press-release/zai-lab-announces-the-appointment-of-dr.-rafael-g.-amado-as-president-head-of-global) Recently, as a corporate insider, he sold 10,787 ADS for $188,033.59 on December 31, 2025.[[3]](https://www.stocktitan.net/sec-filings/ZLAB/144-zai-lab-ltd-sec-filing-bbfbebf72412.html)

View full insider profile →

Trade Price

$18.63

Quantity

2,957

Total Value

$55,083.00

Shares Owned

44,757

Trade Date

Friday, March 13, 2026

5 days ago

SEC Filing Date

Monday, March 16, 2026

Filed 3 days after trade

HEALTHCAREBIOTECHNOLOGY

About Zai Lab Ltd

Company Overview

No company information available
View news mentioning ZLAB

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4838654

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime